91 related articles for article (PubMed ID: 2862826)
1. In vivo sulfation of cholecystokinin octapeptide. Possible interactions of the two forms of cholecystokinin with dopamine in the brain.
Penke B; Kovács GL; Zsigó J; Kádár T; Szabó G; Kovács K; Telegdy G
Ann N Y Acad Sci; 1985; 448():293-305. PubMed ID: 2862826
[TBL] [Abstract][Full Text] [Related]
2. Sulfation and desulfation of cerebral cholecystokinin.
Vargas F; Frerot O; Tuong MD; Zuzel K; Rose C; Schwartz JC
Ann N Y Acad Sci; 1985; 448():110-20. PubMed ID: 3861116
[TBL] [Abstract][Full Text] [Related]
3. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.
Kovács GL; Szabó G; Penke B; Telegdy G
Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum.
Rakovska A
Neurosci Lett; 1995 Aug; 195(3):151-4. PubMed ID: 8584197
[TBL] [Abstract][Full Text] [Related]
5. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin receptor subtypes and neuromodulation.
Altar CA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):381-93. PubMed ID: 2748871
[TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment.
Frey P
Eur J Pharmacol; 1983 Nov; 95(1-2):87-92. PubMed ID: 6141947
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin peptides, dopamine and schizophrenia--a review.
Nair NP; Lal S; Bloom DM
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.
Brodie MS; Dunwiddie TV
Brain Res; 1987 Nov; 425(1):106-13. PubMed ID: 3427413
[TBL] [Abstract][Full Text] [Related]
10. Sulfation of peptides and simple phenols by rat brain phenolsulfotransferase. Inhibition by dichloronitrophenol.
Giorgi O; Meek JL
Biochem Pharmacol; 1985 Jan; 34(1):45-9. PubMed ID: 3855358
[TBL] [Abstract][Full Text] [Related]
11. 3'-Phosphoadenosine 5'-phosphosulfate biosynthesis and the sulfation of cholecystokinin by the tyrosylprotein-sulfotransferase in rat brain tissue.
Vargas F; Frerot O; Brion F; Trung Tuong MD; Lafitte A; Gulat-Marnay C
Chem Biol Interact; 1994 Jun; 92(1-3):281-91. PubMed ID: 8033261
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58.
Fuxe K; Agnati LF; Vanderhaeghen JJ; Tatemoto K; Andersson K; Eneroth P; Härfstrand A; Von Euler G; Toni R; Goldstein M
Ann N Y Acad Sci; 1985; 448():231-54. PubMed ID: 2862825
[TBL] [Abstract][Full Text] [Related]
13. Identification of nonsulfated cholecystokinin-58 in canine intestinal extracts and its biological properties.
Reeve JR; Liddle RA; McVey DC; Vigna SR; Solomon TE; Keire DA; Rosenquist G; Shively JE; Lee TD; Chew P; Green GM; Coskun T
Am J Physiol Gastrointest Liver Physiol; 2004 Aug; 287(2):G326-33. PubMed ID: 15064233
[TBL] [Abstract][Full Text] [Related]
14. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Studies on their functional meaning.
Agnati LF; Fuxe K; Giardino L; Calza L; Zoli M; Battistini N; Benfenati F; Vanderhaeghen JJ; Guidolin D; Ruggeri M
Ann N Y Acad Sci; 1985; 448():315-33. PubMed ID: 2862827
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin turnover in brain.
Meek JL; Iadarola MJ; Giorgi O
Brain Res; 1983 Oct; 276(2):375-8. PubMed ID: 6313133
[TBL] [Abstract][Full Text] [Related]
16. Multiple treatment potentiates the anticonvulsive activity of cholecystokinin octapeptides.
Kádár T; Penke B; Pesti A; Telegdy G
Peptides; 1985; 6(6):1009-14. PubMed ID: 3834411
[TBL] [Abstract][Full Text] [Related]
17. Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration.
Hamilton ME; Redondo JL; Freeman AS
Synapse; 2000 Dec; 38(3):238-42. PubMed ID: 11020226
[TBL] [Abstract][Full Text] [Related]
18. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
Lane RF; Blaha CD; Phillips AG
Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
[TBL] [Abstract][Full Text] [Related]
19. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
Altar CA; Boyar WC
Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological effects of cholecystokinin octapeptide on identified rat nigrostriatal dopaminergic neurons.
Freeman AS; Chiodo LA
Brain Res; 1988 Jan; 439(1-2):266-74. PubMed ID: 3359189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
